Identifying the quantity profiles of amyloid signature proteins in different types of renal amyloidosis

鉴定不同类型肾淀粉样变性中淀粉样蛋白特征蛋白的定量谱

阅读:1

Abstract

BACKGROUND: The aim of this study is to explore the quantity profiles of amyloid signature proteins (serum amyloid P component, SAP; apolipoprotein E, ApoE; apolipoprotein A-IV) in common types of renal amyloidosis by mass spectrometry and immunostaining methods. METHODS: Twenty-one patients with renal amyloidosis of different types evaluated at the Renal Pathological Center of Peking University First Hospital from 2000 to 2021 were enrolled. Immunohistochemistry (IHC) and laser microdissection combining with mass spectrometry (LMD-MS) were applied to investigate the localization and quantity profiles of signature proteins in renal amyloidosis. The co-localization relationships among signature proteins and amyloid fibrils, as well as the ultrastructural localization of SAP were examined by laser scanning confocal microscopy (LSCM) and immuno-electron microscopy (IEM), respectively. RESULTS: By MS-based proteomic analysis, large spectra numbers of ApoE and its higher abundance were noted in four types of amyloidosis when compared with SAP, and ApoA-IV was absent in ALECT2 amyloidosis. LSCM showed ApoE and SAP co-localized with amyloid fibrils in renal AL-κ, AL-λ and ALECT2 amyloidosis. ApoA-IV co-localized with amyloid fibrils in AL-κ and AL-λ amyloidosis, but was not found in ALECT2 amyloidosis. By semi-quantitative analysis based on LSCM and IEM, the quantity levels of signature proteins in AL-κ appeared to be lower than that in AL-λ (P < 0.05) or ALECT2 (P < 0.05), while there was no significant difference between AL-λ and ALECT2 amyloidosis. CONCLUSION: Both of SAP and ApoE were the ubiquitous signature components of renal amyloidosis (AL, AA, ALECT2), as well as ApoA-IV in AL and AA, but not in ALECT2. ApoE was the key signature protein in renal amyloidosis. The quantity levels of signature proteins investigated through LCSM/IEM demonstrated variability among different types, with AL-κ amyloidosis appeared to have a lower level. CLINICAL TRIAL NUMBER: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。